Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.62 |
| ▸ | CTSL | P07711 | 3/20 | 0.61 |
| ▸ | CTSB | P07858 | 2/20 | 0.61 |
| ▸ | CTSS | P25774 | 2/20 | 0.61 |
| ▸ | CTSK | P43235 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | TYR | P14679 | 1/20 | 0.58 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6440663 | 0.94 | CTSL (0.64) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL6440666 | 0.94 | CTSL (0.64) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL10964365 | 0.93 | MMP8 (0.56) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL15080871 | 0.91 | TACR1 (0.68) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL29480462 | 0.89 | CTSL (0.66) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL11199738 | 0.89 | CTSL (0.62) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL18924800 | 0.89 | CTSK (0.58) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL13968379 | 0.88 | ALDH1A1 (0.62) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL7460396 | 0.88 | POLB (0.64) | POLBALDH1A1ALOX15 | |
| Water SCHEMBL27588206 | 0.87 | CTSK (0.53) | TACR1CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670200-B2 | Quaternary ammonium salt prodrugs | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
| US-9580417-B2 | Prodrugs of heteraromatic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-02-28 | — | — | US | disclosed |
| US-20160009713-A1 | Prodrugs of Heteraromatic Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-01-14 | — | — | US | disclosed |
| US-9107911-B2 | Prodrugs of heteraromatic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-08-18 | — | — | US | disclosed |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | ALKERMES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | SLC1A5, IDH1, ASS1 | TACR1 207/4885CTSL 3634/4885CTSB 3633/4885 |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | HTR5A, HTR2C, HTR2B | TACR1 1466/4885CTSL 3126/4885CTSB 2720/4885 |
| US-20160009713-A1 | Prodrugs of Heteraromatic Compounds | CYP2D6, CYP2B6, CYP3A4 | TACR1 479/4885CTSL 1016/4885CTSB 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.